ACR Alpine Capital Research’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$545M Sell
2,146,488
-10,896
-0.5% -$2.54M 7.74% 2
2026
Q1
$527M Sell
2,157,384
-79,664
-4% -$18.6M 7.87% 3
2025
Q4
$463M Buy
2,237,048
+4,972
+0.2% +$983K 7.22% 3
2025
Q3
$414M Buy
2,232,076
+3,134
+0.1% +$537K 7.07% 4
2025
Q2
$340M Buy
2,228,942
+2,383
+0.1% +$366K 6.1% 9
2025
Q1
$369M Buy
2,226,559
+386,322
+21% +$60.4M 7.73% 3
2024
Q4
$266M Buy
1,840,237
+655,818
+55% +$102M 5.77% 8
2024
Q3
$192M Buy
1,184,419
+6,045
+0.5% +$963K 5.67% 10
2024
Q2
$172M Buy
1,178,374
+55,402
+5% +$8.24M 5.32% 10
2024
Q1
$178M Buy
1,122,972
+111,837
+11% +$17.8M 5.39% 11
2023
Q4
$158M Buy
1,011,135
+25,646
+3% +$3.93M 5.35% 10
2023
Q3
$153M Buy
985,489
+30,971
+3% +$5.11M 5.97% 13
2023
Q2
$158M Buy
954,518
+6,793
+0.7% +$1.1M 5.96% 11
2023
Q1
$147M Buy
947,725
+25,695
+3% +$4.15M 5.98% 11
2022
Q4
$163M Sell
922,030
-18,188
-2% -$3.14M 7.31% 7
2022
Q3
$154M Buy
940,218
+24,374
+3% +$4.12M 7.61% 5
2022
Q2
$163M Buy
915,844
+4,129
+0.5% +$736K 7.38% 7
2022
Q1
$162M Buy
911,715
+26,299
+3% +$4.47M 8.02% 8
2021
Q4
$151M Buy
885,416
+165,925
+23% +$27.2M 8.14% 8
2021
Q3
$116M Buy
719,491
+15,040
+2% +$2.57M 6.59% 10
2021
Q2
$116M Sell
704,451
-391
-0.1% -$64.7K 6.37% 10
2021
Q1
$116M Buy
704,842
+8,790
+1% +$1.42M 6.26% 10
2020
Q4
$110M Buy
696,052
+25,681
+4% +$3.79M 6.3% 10
2020
Q3
$99.8M Sell
670,371
-37,648
-5% -$5.57M 7.1% 6
2020
Q2
$99.6M Sell
708,019
-56,574
-7% -$8.24M 6.61% 8
2020
Q1
$100M Sell
764,593
-13,878
-2% -$1.97M 6.66% 6
2019
Q4
$114M Sell
778,471
-27,681
-3% -$3.75M 5.91% 6
2019
Q3
$104M Buy
806,152
+22,641
+3% +$2.98M 5.26% 7
2019
Q2
$109M Sell
783,511
-38,603
-5% -$5.34M 5.77% 8
2019
Q1
$115M Sell
822,114
-15,837
-2% -$2.12M 5.92% 7
2018
Q4
$108M Sell
837,951
-8,299
-1% -$1.16M 5.53% 6
2018
Q3
$117M Buy
846,250
+2,821
+0.3% +$375K 6.2% 7
2018
Q2
$102M Buy
843,429
+60,867
+8% +$7.59M 5.5% 8
2018
Q1
$100M Sell
782,562
-31,069
-4% -$4.2M 5.45% 8
2017
Q4
$114M Sell
813,631
-20,622
-2% -$2.87M 6.03% 7
2017
Q3
$108M Sell
834,253
-26,919
-3% -$3.57M 5.86% 6
2017
Q2
$114M Sell
861,172
-49,261
-5% -$6.28M 9.79% 3
2017
Q1
$113M Buy
910,433
+1,916
+0.2% +$229K 9.73% 4
2016
Q4
$105M Sell
908,517
-92,998
-9% -$10.7M 8.45% 3
2016
Q3
$118M Buy
1,001,515
+12,869
+1% +$1.56M 8.19% 5
2016
Q2
$120M Sell
988,646
-20,862
-2% -$2.37M 9.18% 3
2016
Q1
$109M Buy
1,009,508
+21,139
+2% +$2.19M 8.7% 3
2015
Q4
$102M Buy
988,369
+34,073
+4% +$3.43M 10.16% 4
2015
Q3
$89.1M Buy
954,296
+51,643
+6% +$5M 9.76% 4
2015
Q2
$88M Buy
902,653
+61,900
+7% +$6.2M 10.98% 4
2015
Q1
$84.6M Buy
840,753
+118,685
+16% +$12.1M 10.28% 3
2014
Q4
$75.5M Buy
722,068
+52,466
+8% +$5.53M 9.92% 3
2014
Q3
$71.4M Buy
669,602
+39,108
+6% +$4.06M 10.65% 3
2014
Q2
$66M Buy
630,494
+15,011
+2% +$1.52M 10.09% 4
2014
Q1
$60.5M Buy
615,483
+123,299
+25% +$11.4M 10.07% 3
2013
Q4
$45.1M Buy
492,184
+31,812
+7% +$2.93M 9.09% 7
2013
Q3
$39.9M Buy
460,372
+38,610
+9% +$3.46M 9.29% 5
2013
Q2
$36.2M Buy
+421,762
New +$35.8M 8.23% 3

Other funds holding JNJ

ACR Alpine Capital Research's JNJ Position: Q2 2026 in Review

ACR Alpine Capital Research reduced its Johnson & Johnson (JNJ) stake by 0.51% in Q2 2026, selling an estimated $2.54M and leaving 2,146,488 shares worth $545M. The position accounts for 7.74% of the portfolio, ranked #2.

ACR Alpine Capital Research first reported a position in JNJ in Q2 2013 and has held it in 53 quarters since. 4,649 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • ACR Alpine Capital Research held 2,146,488 shares of Johnson & Johnson worth $545M as of Q2 2026.
  • ACR Alpine Capital Research sold 10,896 Johnson & Johnson shares in Q2 2026, an estimated $2.54M.
  • Johnson & Johnson made up 7.74% of ACR Alpine Capital Research's portfolio in Q2 2026, its #2 holding.
  • ACR Alpine Capital Research first reported a position in Johnson & Johnson in Q2 2013 and has held it in 53 quarters since.
  • 4,649 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on ACR Alpine Capital Research's 13F filing for Q2 2026, filed 29 Jul 2026.